Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252890 | 0.81 | CES1 (0.46) | CES1SRCMAPTTSHRCYP3A4 | |
| SCHEMBL1395461 | 0.81 | CES1 (0.50) | CES1SRCMAPTTSHRCYP3A4 | |
| SCHEMBL6253264 | 0.79 | CES1 (0.41) | CES1SRCMAPTTSHRCYP3A4 | |
| SCHEMBL754131 | 0.78 | CES1 (0.47) | CES1SRCMAPTTSHRHSD17B10 | |
| SCHEMBL11667577 | 0.77 | CES1 (0.42) | CES1SRCMAPTTSHRCYP3A4 | |
| SCHEMBL4769359 | 0.77 | KCNN4 (0.48) | CES1SRCMAPTTSHRCYP3A4 | |
| SCHEMBL5928512 | 0.75 | CES1 (0.45) | CES1SRCTSHRCYP2C19KMT2A | |
| SCHEMBL1508202 | 0.74 | CES1 (0.56) | CES1SRCMAPTTSHRCYP3A4 | |
| SCHEMBL15519395 | 0.74 | CES1 (0.56) | CES1SRCMAPTTSHRCYP3A4 | |
| SCHEMBL5843722 | 0.74 | ALDH1A1 (0.44) | CES1SRCMAPTCYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258969-A1 | Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers | GALECTIN THERAPEUTICS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258969-A1 | Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers | CD44, ALG1, FUT6 | CES1 2251/4885SRC 369/4885MAPT 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.